Drug Type Small molecule drug |
Synonyms Ecabet, Ecabet Sodium, Ecabet Sodium Granules + [7] |
Target- |
Action inhibitors |
Mechanism Urease inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (01 Oct 1993), |
Regulation- |
Molecular FormulaC20H28NaO5S |
InChIKeyJNTMHWBQZJIWMT-YGJXXQMASA-N |
CAS Registry86408-72-2 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Acute gastritis | Japan | 22 Nov 1995 | |
| Chronic gastritis | Japan | 22 Nov 1995 | |
| Stomach Ulcer | Japan | 01 Oct 1993 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Phase 3 | Japan | - | |
| Dry Eye Syndromes | Phase 2 | United States | - | |
| Dry Eye Syndromes | Phase 2 | Japan | - |
Phase 2 | 183 | (Ecabet Ophthalmic Solution) | yfengxrgqp(nsbqtxawaj) = xgqxlazuri xkbrxvhsvl (uxubamilal, 4.70) View more | - | 03 Sep 2020 | ||
placebo (Vehicle) | yfengxrgqp(nsbqtxawaj) = swfkltwifz xkbrxvhsvl (uxubamilal, 4.40) View more |





